FDA approves drug combination for skin cancer

20 Nov 2015

Novartis received U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of skin cancer.

The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years overall survival in patients, the company said.


The combination was initially approved based on mid-stage data through the FDA's accelerated approval program, but the approval was contingent on data from late-stage trial.

Source: Reuters

Login to your account

Did you forget your password?